Literature DB >> 11150354

Amyloid-beta peptides are cytotoxic to oligodendrocytes.

J Xu1, S Chen, S H Ahmed, H Chen, G Ku, M P Goldberg, C Y Hsu.   

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive dementia. Amyloid-beta peptide (Abeta), a 39-43 amino acid peptide derived from beta-amyloid precursor protein, forms insoluble fibrillar aggregates that have been linked to neuronal and vascular degeneration in AD and cerebral amyloid angiopathy. Here we demonstrate that Abeta 1-40 and a truncated fragment, Abeta 25-35, induced death of oligodendrocytes (OLGs) in vitro in a dose-dependent manner with similar potencies. Abeta-induced OLG death was accompanied by nuclear DNA fragmentation, mitochondrial dysfunction, and cytoskeletal disintegration. Abeta activation of redox-sensitive transcription factors NF-kappaB and AP-1 and antioxidant prevention of Abeta-mediated OLG death suggest that oxidative injury contributes to Abeta cytotoxicity in OLGs. Recent demonstration of Abeta deposition and white matter abnormalities in AD implies a potential pathophysiological role for Abeta-mediated cytotoxicity of OLGs in this neurodegenerative disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11150354      PMCID: PMC6762453     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  62 in total

1.  Homocysteine and folate deficiency sensitize oligodendrocytes to the cell death-promoting effects of a presenilin-1 mutation and amyloid beta-peptide.

Authors:  Kirk J Pak; Sic L Chan; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

2.  Mapping the structural brain changes in Alzheimer's disease: the independent contribution of two imaging modalities.

Authors:  Elisa Canu; Donald G McLaren; Michele E Fitzgerald; Barbara B Bendlin; Giada Zoccatelli; Franco Alessandrini; Francesca B Pizzini; Giuseppe K Ricciardi; Alberto Beltramello; Sterling C Johnson; Giovanni B Frisoni
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

3.  Optimal promoter usage for lentiviral vector-mediated transduction of cultured central nervous system cells.

Authors:  Mingjie Li; Nada Husic; Ying Lin; Heather Christensen; Ibrahim Malik; Sally McIver; Christine M LaPash Daniels; David A Harris; Paul T Kotzbauer; Mark P Goldberg; B Joy Snider
Journal:  J Neurosci Methods       Date:  2010-03-27       Impact factor: 2.390

4.  A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease.

Authors:  Walter J Lukiw; Jian-Guo Cui; Victor L Marcheselli; Merete Bodker; Anja Botkjaer; Katherine Gotlinger; Charles N Serhan; Nicolas G Bazan
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

Review 5.  Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature.

Authors:  Tony Wyss-Coray; Joseph Rogers
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

6.  Frontal white matter integrity in adults with Down syndrome with and without dementia.

Authors:  David Powell; Allison Caban-Holt; Gregory Jicha; William Robertson; Roberta Davis; Brian T Gold; Frederick A Schmitt; Elizabeth Head
Journal:  Neurobiol Aging       Date:  2014-02-04       Impact factor: 4.673

7.  Age and Alzheimer's pathology disrupt default mode network functioning via alterations in white matter microstructure but not hyperintensities.

Authors:  Christopher A Brown; Yang Jiang; Charles D Smith; Brian T Gold
Journal:  Cortex       Date:  2018-04-19       Impact factor: 4.027

Review 8.  Oxidative stress signaling in Alzheimer's disease.

Authors:  B Su; X Wang; A Nunomura; P I Moreira; H-gon Lee; G Perry; M A Smith; X Zhu
Journal:  Curr Alzheimer Res       Date:  2008-12       Impact factor: 3.498

9.  Alzheimer's peptide and serine proteinase inhibitors in glaucoma and exfoliation syndrome.

Authors:  Sabina Janciauskiene; Torsten Krakau
Journal:  Doc Ophthalmol       Date:  2003-05       Impact factor: 2.379

10.  Triple-transgenic Alzheimer's disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology.

Authors:  Maya K Desai; Kelly L Sudol; Michelle C Janelsins; Michael A Mastrangelo; Maria E Frazer; William J Bowers
Journal:  Glia       Date:  2009-01-01       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.